Buy Hexarelin Research Peptide

What is Hexarelin?

Hexarelin is a synthetic six-amino-acid peptide that strongly activates the ghrelin receptor. It is also studied for a separate signaling route in heart tissue (through the CD36 receptor) that works independently of growth-hormone release.

• A six-amino-acid peptide that activates the ghrelin receptor with high potency
• One of the strongest ghrelin-receptor activators known; used as a reference compound
• Studied for a separate signaling route in heart tissue through the CD36 receptor
• Investigated in animal heart-tissue research for CD36-related signaling

For research use only. Not approved for human therapeutic use.

Hexarelin (CAS 140703-51-1), also known as Examorelin, is a synthetic hexapeptide growth hormone secretagogue with the molecular formula C47H58N12O6 and a molecular weight of 887.05 g/mol. Its amino acid sequence, His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2, features a 2-methyl-D-tryptophan residue at position 2, a structural modification considered significant to its receptor binding characteristics and resistance to proteolytic degradation. Produced via solid-phase peptide synthesis, Hexarelin acts as an agonist at the ghrelin receptor (GHS-R1a) and is one of the most frequently cited secretagogues in preclinical endocrine and cardiovascular research.

Hexarelin occupies a notable position in preclinical research due to the breadth of biological pathways it has been investigated alongside. In vitro studies in receptor binding preparations using human brain and pituitary tissue have examined its binding affinity at the GHS-R1a receptor and its capacity to stimulate intracellular calcium mobilisation in pituitary cell lines, with published work characterising specific GHS-R1a binding parameters and investigating its resistance to enzymatic degradation relative to earlier secretagogues such as GHRP-6 [1]. Beyond the somatotropic axis, Hexarelin has also been investigated in rodent cardiovascular models, where researchers have examined its interaction with isolated cardiac and myocardial tissue preparations, documenting cardiac activity independent of GH-mediated pathways, an area of investigation that distinguishes it from most other compounds in the secretagogue class [2].

Hexarelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, et al. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J Endocrinol. 1998 Apr;157(1):99–106. .PubMed PMID: 96143632Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999 Sep;140(9):4024–31. .PubMed PMID: 10465272

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Hexarelin (CAS 140703-51-1), also known as Examorelin, is a synthetic hexapeptide growth hormone secretagogue with the molecular formula C47H58N12O6 and a molecular weight of 887.05 g/mol. Its amino acid sequence, His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2, features a 2-methyl-D-tryptophan residue at position 2, a structural modification considered significant to its receptor binding characteristics and resistance to proteolytic degradation. Produced via solid-phase peptide synthesis, Hexarelin acts as an agonist at the ghrelin receptor (GHS-R1a) and is one of the most frequently cited secretagogues in preclinical endocrine and cardiovascular research.

Hexarelin occupies a notable position in preclinical research due to the breadth of biological pathways it has been investigated alongside. In vitro studies in receptor binding preparations using human brain and pituitary tissue have examined its binding affinity at the GHS-R1a receptor and its capacity to stimulate intracellular calcium mobilisation in pituitary cell lines, with published work characterising specific GHS-R1a binding parameters and investigating its resistance to enzymatic degradation relative to earlier secretagogues such as GHRP-6 [1]. Beyond the somatotropic axis, Hexarelin has also been investigated in rodent cardiovascular models, where researchers have examined its interaction with isolated cardiac and myocardial tissue preparations, documenting cardiac activity independent of GH-mediated pathways, an area of investigation that distinguishes it from most other compounds in the secretagogue class [2].

Hexarelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, et al. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J Endocrinol. 1998 Apr;157(1):99–106. .PubMed PMID: 96143632Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999 Sep;140(9):4024–31. .PubMed PMID: 10465272

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number140703-51-1Molecular Weight887.05 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUHEX

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Hexarelin (CAS 140703-51-1), also known as Examorelin, is a synthetic hexapeptide growth hormone secretagogue with the molecular formula C47H58N12O6 and a molecular weight of 887.05 g/mol. Its amino acid sequence, His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2, features a 2-methyl-D-tryptophan residue at position 2, a structural modification considered significant to its receptor binding characteristics and resistance to proteolytic degradation. Produced via solid-phase peptide synthesis, Hexarelin acts as an agonist at the ghrelin receptor (GHS-R1a) and is one of the most frequently cited secretagogues in preclinical endocrine and cardiovascular research.

Hexarelin occupies a notable position in preclinical research due to the breadth of biological pathways it has been investigated alongside. In vitro studies in receptor binding preparations using human brain and pituitary tissue have examined its binding affinity at the GHS-R1a receptor and its capacity to stimulate intracellular calcium mobilisation in pituitary cell lines, with published work characterising specific GHS-R1a binding parameters and investigating its resistance to enzymatic degradation relative to earlier secretagogues such as GHRP-6 [1]. Beyond the somatotropic axis, Hexarelin has also been investigated in rodent cardiovascular models, where researchers have examined its interaction with isolated cardiac and myocardial tissue preparations, documenting cardiac activity independent of GH-mediated pathways, an area of investigation that distinguishes it from most other compounds in the secretagogue class [2].

Hexarelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, et al. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J Endocrinol. 1998 Apr;157(1):99–106. .PubMed PMID: 96143632Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999 Sep;140(9):4024–31. .PubMed PMID: 10465272

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number140703-51-1Molecular Weight887.05 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUHEX

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.